Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
For an industry whose central structural dilemma is the slow pace of progress from bench to bedside, GE stands out as an exemplar of success – its performance on speed-to-market product launch has been studied extensively by big pharma strategists. GE Healthcare’s Tom McGuinness tells In Vivo how his division is doubling down on this record, using software and data analytics to help biopharma become more efficient in moving products to patients.
Latest From Leadership
Pfizer, an early leader in putting patients forward in the conduct of clinical trials, is continuing to test ways to move beyond process improvements to more ambitious initiatives at the front end of technology innovation.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The UK continues to press for favorable trading and regulatory conditions with the EU in its Brexit planning. But EU negotiators seem likely to play it by the book, with no favors shown. The medtech industry watched as the EU withdrawal agreement was approved by the EU27 at the March 2018 Euro Summit. Some weeks prior to that, MedTech Europe chief executive Serge Bernasconi told In Vivo of his fears for EU medtech if the industry was too slow in preparing for UK withdrawal.
Industry veteran Tadataka Yamada draws on his multidisciplinary background for perspectives on what’s new – and what isn’t – in a field where every researcher has at some point experienced the same teachable moment: when you strive to make a medicine, so many things can go wrong.
It seems only a matter of time that the leaders of established biopharma will need to redefine core functions such as research, manufacturing and marketing around a new vision.
The waiting is over and digital technologies are being adopted at pace, according to a CEOs Unfiltered panel at MedTech Europe's 2018 Forum. Connected care is at the top of the priority list, say Siemens Healthineers' Bernd Montag, AdvaMed Chairman/CVRx President and CEO Nadim Yared and former bioMerieux President and CEO Jean-Luc Bélingard, although it's not the only pressing issue on the bill.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.